The abstract is read at the publisher; the summary is JClub's.
Withdrawal of Medicaid coverage for weight loss–approved glucagon-like peptide-1s is examined for its association with beneficiaries’ utilization using Medicaid State Drug Utilization Data.
- Why it matters: Coverage changes may alter access to weight loss medications, but the extent to which utilization shifts after withdrawal is unclear.
- What they did: A cross-sectional analysis uses Medicaid State Drug Utilization Data to assess associations between coverage withdrawal and use of weight loss–approved glucagon-like peptide-1s.
- The result: The study characterizes how utilization of these GLP-1s is linked to Medicaid coverage withdrawal, informing expectations about medication uptake after policy changes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.